An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Barclays Appoints Jefferson Rives as a Managing Director in Healthcare Investment Banking
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Barclays has appointed Jefferson Rives as a Managing Director in Healthcare Investment Banking, focusing on healthcare services, IT, payer, and pharma supply chain. Rives brings over 15 years of experience, previously working at Wells Fargo and Morgan Stanley, and has been involved in transactions exceeding $175bn. This hiring follows recent appointments in the healthcare sector, as Barclays aims to enhance its business momentum in healthcare services.
Positive
Jefferson Rives brings over 15 years of experience in healthcare investment banking.
Rives has led high-profile transactions, indicating strong industry connections.
Barclays continues to bolster its leadership in healthcare investment banking.
Negative
Concerns regarding continuity and experience gaps due to a significant leadership change.
NEW YORK--(BUSINESS WIRE)--
Barclays announces the appointment of Jefferson Rives as a Managing Director in Healthcare Investment Banking. Mr. Rives will be based in New York, and will focus on healthcare services including IT, payer and pharma supply chain. He will report to Rick Landgarten, Global Head of Healthcare & Real Estate Groups at Barclays.
Mr. Rives joins Barclays with over fifteen years of industry experience, most recently as a Managing Director in Healthcare Investment Banking at Wells Fargo. Prior to joining Wells Fargo in 2015, Mr. Rives worked in the Global Healthcare Banking team at Morgan Stanley, and before that from 2011 worked at Jefferies & Company in the Global Healthcare Group. Mr. Rives has been involved in corporate advisory and financing transactions totaling over $175bn in value during his career to date, and has extensive experience in HCIT, Pharmacy Supply Chain, and Employer, Payer, and Provider Services. He has led the origination and execution of a number of high-profile transactions, including advising PANTHERx Rare Pharmacy on its sale to Centene, advising MeMD on the company’s sale to Walmart, and serving as bookrunner on equity deals for Phreesia, One Medical, Omnicell, Allscripts, and Change Healthcare.
“Jefferson has outstanding knowledge of the healthcare services space, and his extensive transactional experience and deep roster of key relationships will deliver great value for our clients,” said Rick Landgarten, Global Head of Healthcare & Real Estate Groups. “We look forward to succeeding together as a team, and further accelerating our HCIT and broader Healthcare business momentum.”
Mr. Rives’ hire follows Barclays’ recent appointments of Amit Tyagi as a Managing Director focusing on the Tools and Diagnostics sector, and Naeem Merchant as a Managing Director focusing on the Pharmaceutical Services and IT sectors.
Barclays has performed lead roles in a number of recent transactions of note in the Healthcare Banking space, including serving as financial advisor to Thermo Fisher Scientific on their pending $21bn acquisition of PPD, and acting as financial advisor to Centene Corporation in the company’s $3.1bn acquisition of Magellan Health, Inc. Barclays acted as financial advisor to Kindred at Home on their sale to Humana, and served as financial advisor to HMS on the company’s sale to Veritas Capital-backed Gainwell Technologies for $3.4bn. Barclays also acted as lead left bookrunner and stabilization agent on a $388mm follow on offering for R1 RCM Inc. In addition, Barclays has performed key roles in several recent IPOs of note, including serving as a senior active bookrunner on a $649mm IPO for Signify Health, Inc., as an active bookrunner on a $924mm IPO for Bright Health Group, Inc., and as an active bookrunner on a $1.3bn IPO for GoodRx Holdings, Inc.
Barclays is a British universal bank. We are diversified by business, by different types of customer and client, and geography. Our businesses include consumer banking and payments operations around the world, as well as a top-tier, full service, global corporate and investment bank, all of which are supported by our service company which provides technology, operations and functional services across the Group. For further information about Barclays, please visit our website www.barclays.com. Barclays offers investment banking products and services in the US through Barclays Capital Inc.
Who is Jefferson Rives and what will be his role at Barclays?
Jefferson Rives is appointed as a Managing Director in Healthcare Investment Banking at Barclays, focusing on healthcare services including IT, payer, and pharma supply chain.
What is Jefferson Rives' background before joining Barclays?
Prior to Barclays, Rives was a Managing Director at Wells Fargo and has extensive experience in healthcare investment banking with firms like Morgan Stanley and Jefferies.
How might Rives' appointment impact Barclays' healthcare investment banking sector?
Rives' extensive experience and industry connections could enhance Barclays' business momentum and client offerings in healthcare investment banking.
What recent appointments has Barclays made in its healthcare division?
Barclays recently appointed Amit Tyagi and Naeem Merchant as Managing Directors focusing on the Tools and Diagnostics sector and Pharmaceutical Services and IT sectors respectively.
What notable transactions has Barclays recently been involved in within the healthcare sector?
Barclays has acted as financial advisor in significant transactions like Thermo Fisher's $21bn acquisition of PPD and Centene Corporation's $3.1bn acquisition of Magellan Health.